Bortezomib in the treatment of multiple myeloma

Bortezomib in the treatment of multiple myeloma

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promisin...

Descripció completa

Dades bibliogràfiques
Publicat a:Springer eBooks.
Autor corporatiu: SpringerLink (Online service)
Altres autors: Ghobrial, Irene M., Richardson, Paul G., Anderson, Kenneth C.
Format: Electronic Resource
Idioma:English
Publicat: Basel Springer Basel c2011.
Matèries:
Multiple myeloma > Treatment.
Multiple myeloma > Chemotherapy.
Antineoplastic agents.
Boronic Acids > Therapeutic use.
Multiple myeloma > Drug therapy.
Antineoplastic agents > Therapeutic use.
Protease inhibitors > Therapeutic use.
Proteasome endopeptidase complex > Antagonists & inhibitors.
Pyrazines > Therapeutic use.
Electronic books.
Accés en línia:Available for University of the Philippines Diliman via SpringerLink. Click here to access